文献速递结核与非结核分枝杆菌艾滋病与性传播感染

新型结核诊断技术对社区强化病例发现的影响:多中心随机对照试验

Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2017-01-05

该研究在南非开普敦和津巴布韦哈拉雷结核与HIV高流行社区开展实用性随机对照试验,比较痰Xpert-MTB/RIF(HIV感染者加用尿Determine TB LAM)与痰涂片镜检用于强化病例发现的效果。

要点

  • 社区强化病例发现中,Xpert-MTB/RIF较痰涂片提高培养阳性结核患者启动治疗比例
  • HIV感染者加用尿LAM在该场景未显示额外获益
  • 仅1例培养阳性患者基于LAM阳性启动治疗

核心结论

  • 在HIV和结核高流行社区,Xpert-MTB/RIF用于强化病例发现可提高培养阳性结核患者启动治疗的比例。
  • 尿LAM检测在该强化病例发现场景中未显示有用性。

研究设计与样本

  • 实用性、随机、平行组试验,个体随机化并按国家分层,1:1分组,以培养为参考标准。
  • 在南非开普敦和津巴布韦哈拉雷结核与HIV高流行社区开展,筛查2261人,875人(39%)符合诊断检测标准,随机分组439例(新型诊断组)和436例(常规诊断组)。

主要发现

  • 875名参与者中74人(9%)确诊结核。
  • 排除晚期培养阳性启动治疗者后,新型诊断组60天内启动治疗36/42(86%),常规诊断组18/32(56%)。
  • 仅1例培养阳性患者基于LAM阳性启动治疗。

临床怎么用

  • 在HIV和结核高流行社区的强化病例发现中,可考虑使用Xpert-MTB/RIF替代痰涂片镜检以提高培养阳性患者的治疗启动率。
  • 该场景下不建议常规加用尿LAM检测用于强化病例发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequate case detection results in high levels of undiagnosed tuberculosis in sub-Saharan Africa. Data for the effect of new diagnostic tools when used for community-based intensified case finding are not available, so we investigated whether the use of sputum Xpert-MTB/RIF and the Determine TB LAM urine test in two African communities could be effective. METHODS: In a pragmatic, randomised, parallel-group trial with individual randomisation stratified by country, we compared sputum Xpert-MTB/RIF, and if HIV-infected, the Determine TB LAM urine test (novel diagnostic group), with laboratory-based sputum smear microscopy (routine diagnostic group) for intensified case finding in communities with high tuberculosis and HIV prevalence in Cape Town, South Africa, and Harare, Zimbabwe. Participants were randomly assigned (1:1) to these groups with computer-generated allocation lists, using culture as the reference standard. In Cape Town, participants were randomised and tested at an Xpert-equipped mobile van, while in Harare, participants were driven to a local clinic where the same diagnostic tests were done. The primary endpoint was the proportion of culture-positive tuberculosis cases initiating tuberculosis treatment in each study group at 60 days. This trial is registered at ClinicalTrials.gov, number NCT01990274. FINDINGS: Between Oct 18, 2013, and March 31, 2015, 2261 individuals were screened and 875 (39%) of these met the criteria for diagnostic testing. 439 participants were randomly assigned to the novel group and 436 to the routine group. 74 (9%) of 875 participants had confirmed tuberculosis. If late culture-based treatment initiation was excluded, more patients with culture-positive tuberculosis were initiated on treatment in the novel group at 60 days (36 [86%] of 42 in the novel group vs 18 [56%] of 32 in the routine group). Thus the difference in the proportion initiating treatment between groups was 29% (95% CI 9-50, p=0·0047) and 53% more patients initiated therapy in the novel diagnostic group than in the routine diagnostic group. One culture-positive patient was treated based only on a positive LAM test. INTERPRETATION: Compared with traditional tools, Xpert-MTB/RIF for community-based intensified case finding in HIV and tuberculosis-endemic settings increased the proportion of patients initiating treatment. By contrast, urine LAM testing was not found to be useful for intensive case finding in this setting. FUNDING: European and Developing Countries Clinical Trials Partnership and South African Medical Research Council.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Calligaro GL, Zijenah LS, Peter JG, et al. Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infect Dis. 2017. PMID: 28063795. doi:10.1016/S1473-3099(16)30384-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。